H.C. Wainwright analyst Sean Lee raised the firm’s price target on Novavax (NVAX) to $16 from $11 and keeps a Buy rating on the shares. The firm says the company’s Pfizer agreement is “the first of many” as it shifts towards a “high-margin” licensing model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX: